RxDoctor Payments Data

Luca de Simone, MD

Internal Medicine · Woodbridge, NJNPI 1104897388

Payments from drug & device makers

$954in general payments, 2019–2025

Across 24 payments — averaging $39.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$247
  • Amgen$220
  • AstraZeneca$154
  • Boston Scientific$120
  • Nxstage Medical, Inc.$95
  • Fresenius USA Marketing, Inc.$32
  • plus $86 from 5 others

What the payments were for

  • Food & beverage$84188%
  • Education$11312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$954 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$125,415
Medicare patients
161
Services billed
1,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$23,231
FarxigaDapagliflozin Propanediol23$14,022
Breo ElliptaFluticasone/Vilanterol11$4,513
Calcium Acetate15$3,679
Novolog FlexpenInsulin Aspart13$1,787
Atorvastatin Calcium89$1,067
ClopidogrelClopidogrel Bisulfate59$1,013
Tamsulosin Hcl23$763
Pantoprazole Sodium26$652
Metoprolol Succinate32$623
Losartan Potassium31$559
Levetiracetam15$446
Valsartan11$391
Finasteride13$334
Metformin Hcl26$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$154$14,02223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Woodbridge

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →